REFRACTORY GRADE 3B FOLLICULAR LYMPHOMA
Clinical trials for REFRACTORY GRADE 3B FOLLICULAR LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY GRADE 3B FOLLICULAR LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY GRADE 3B FOLLICULAR LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy aims to unmask lymphoma cells to the immune system
Disease control OngoingThis study tests a combination of two drugs, TTI-622 and pembrolizumab, in people with diffuse large B-cell lymphoma that has returned or stopped responding to treatment. TTI-622 blocks a protein called CD47 that cancer cells use to hide from the immune system, while pembrolizuma…
Matched conditions: REFRACTORY GRADE 3B FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 15, 2026 18:57 UTC
-
Experimental combo aims to supercharge immune cells against Hard-to-Treat lymphoma
Disease control OngoingThis early-phase trial studies whether adding an experimental drug called NKTR-255 to standard CAR-T cell therapy can safely improve outcomes for adults with large B-cell lymphoma that has returned or not responded to treatment. The drug is designed to boost the immune system's c…
Matched conditions: REFRACTORY GRADE 3B FOLLICULAR LYMPHOMA
Phase: PHASE1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 12, 2026 12:03 UTC
-
New drug cocktail shows promise against Hard-to-Treat lymphoma
Disease control OngoingThis study tests a combination of three drugs—ALX148, rituximab, and lenalidomide—in people with B-cell non-Hodgkin lymphoma that has come back or not responded to prior treatment. The goal is to find the best dose and see how well the combo controls the cancer. About 47 adults w…
Matched conditions: REFRACTORY GRADE 3B FOLLICULAR LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 02, 2026 11:57 UTC